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Abstract
Background: Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin which plays survival- and growth-
promoting activity in neuronal cells and it is involved in cellular plasticity mechanisms as it controls activity
dependent synaptic transmission. A functional polymorphism (Val66Met) in the pro-region of BDNF, which affects
the intracellular trafficking of proBDNF has been associated with memory and cognitive deficits as well as to an
increased susceptibility for several psychiatric disorders especially those with a neurodevelopmental origin. To date,
no study has evaluated the influence of the Val66Met polymorphism on BDNF levels in a peripheral system that
may reflect fetal neurodevelopment. Therefore we investigated in amniotic fluids (AF) obtained from 139 healthy
women during 15-17 week of pregnancy, BDNF protein levels in correlation with the Val66Met polymorphism.
Results: Interestingly we found a significant BDNF protein levels reduction in 55 Met carriers (Val/Met and Met/
Met) (p = 0.002) as compared to 84 non carriers (Val/Val), and no effect of fetus gender, maternal age or gestation
week on BDNF levels has been observed.
Conclusion: These results, although explorative, indicate that during fetal life the Val66Met genotype might
influences BDNF protein levels in AF supporting the involvement of this polymorphism in behavioral and
functional brain individual differences in the adulthood.
Background
Brain-Derived Neurotrophic Factor (BDNF) is a neuro-
trophin widely expressed in the brain, which regulates
neuronal survival, growth and connectivity during devel-
opment and participates in synaptic plasticity mechan-
isms throughout adult life [1]. BDNF has been detected
in several brain regions with the highest expression
levels in hippocampus, cortex and cerebellum and in
different non neuronal tissues like thymus, liver, spleen,
heart, lung, immune system cells and Amniotic Fluid
(AF) [2,3]. Interestingly, altered BDNF AF levels were
found associated with Central Nervous System (CNS)
abnormalities of the fetus, suggesting that AF BDNF
levels could be indicative of fetal CNS development [4].
BDNF protein is first synthesized as a glycosylated
precursor (proBDNF) that is then converted intracellu-
lary to mature BDNF protein, the latter being stored
and released upon cell stimulation [5]. An aminoacid
substitution from Valine to Methionine due to a single-
nucleotide polymorphism at the codon 66 has been
identified in the propeptide region of BDNF (Val66Met).
Egan and co-workers have demonstrated “in vitro” the
functional relevance of this substitution since the geno-
type can affect the intracellular trafficking of proBDNF
leading to reduced activity-dependent secretion of the
neurotrophin. In turn, lower activity-dependent secre-
tion of the neurotrophin is associated with the Met
allele as compared to the Val allele [6,7]. The function-
ality of the polymorphism has also been supported by
several findings in humans that reported an effect of
genotype on memory and cognitive performances
[6,8-10]. Moreover, recent magnetic resonance imaging
(MRI) studies evidenced an effect of the Val66Met poly-
morphism on brain morphology, with Met carriers hav-
ing reduced volume of different brain structures,
including hippocampus, parahippocampal gyrus and pre-
frontal cortex [11,12].
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Furthermore, the Val66Met polymorphism has also
been widely investigated as a genetic susceptibility risk
factor for a large spectrum of neuropsychiatric disorders,
in particular those with a neurodevelopmental origin
[13-17] leading often to contrasting results. Conversely,
positive associations of the BDNF Val66Met have been
reported with specific symptoms of depressive disorders
[18], or schizophrenia and again, with specific illness
morpho-functional endophenotypes [19] associated to
brain development and functionality like a reduced hip-
pocampal volume or a deficit in cognitive performances
[19-21].
To date, at our best knowledge, no study has evalu-
ated the putative influence of the Val66Met polymorph-
ism on BDNF levels during pregnancy, a period during
which fetal brain development appears vulnerable to
external stimuli. In fact, it is well accepted that adverse
events occurring during fetal life have profound and
persistent effects on brain functions and may represent
risk factors for psychopathologies later in life [22,23].
Therefore the aim of this study was to analyze puta-
tive functional effects of the BDNF Val66Met poly-
morphism in the fetal environment investigating
correlation between BDNF protein levels and genotype
in a sample of AFs obtained at the 15th-17th gestational
week of physiological pregnancies.
Results
The BDNF fetal genotype distribution in our study
population was 3.6% (5/139) for Met/Met, 36% (50/139)
for Val/Met and 60.4% (84/139) for Val/Val. Genotype
distribution had no deviation from Hardy-Weinberg
equilibrium (c2 = 0.55, p = 0.46, HWE program, John
Ott version 1.10). Since all the studies that evaluated the
functionality of this polymorphism assembled Val/Met
individuals with Met/Met and it has also been demon-
strated that the Met allele has a dominant effect, we
performed our analyses subdividing our study-sample
into carriers (Met66Met, Val66Met) and non carriers
(Val66Val homozygotes) of the Met allele.
We firstly assessed whether maternal age or gesta-
tional week was significantly different in Met carriers
versus non carriers, but we didn’t find any difference
(mean values ± SD: gestational age = 16.2 ± 2.4 in Val/
Val and 15.9 ± 0.7 in Met carriers, p = 0.314; maternal
age = 35.4 ± 3.7 in Val/Val and 36.2 ± 3.1 in Met car-
riers); there was also a similar fetal gender distribution
among carriers and non carriers of the Met allele (49.1%
of females in Met carriers and 44.0% of females in non
carriers).
We subsequently evaluated BDNF levels in AFs and
we found that BDNF protein levels were significantly
lower in Met allele carriers when compared to non car-
riers. In fact, as shown in Figure 1, the amount of
BDNF expressed in pg/ml was 10.02 ± 9.62 for Met car-
riers and 15.88 ± 12.71 for non carriers (Mann-Whith-
ney Test: p = 0.002). In addition no effect of the
covariates maternal age, gestational week and fetal gen-
der was found on BDNF levels (p = 0.672, p = 0.833
and p = 0.194 respectively).
Discussion
This study represents the first evidence of an effect of
the BDNF Val66Met polymorphism on protein levels
during the 15-17 weeks of pregnancy.
Egan and colleagues [6] have shown in their seminal
paper the functional relevance of the Val66Met poly-
morphism, demonstrating that BDNF genotype affects
the intracellular trafficking of the neurotrophin, suggest-
ing that there may be a specific ‘trafficking’ signal in the
pro-domain of BDNF, which is required for an efficient
sorting of the neurotrophin to the regulated secretory
pathway. Moreover, they demonstrated that the geno-
type can also affect the activity-dependent release of
BDNF [5] as recently confirmed by Chen and colleagues
[24]. The decreased intracellular BDNF trafficking and
release due to the presence of the Met allele are thought
to underlie several dysfunctions in humans. In fact, indi-
viduals carrying the Met allele show reduced grey mat-
ter volumes within brain regions known to participate in
verbal memory and visuospatial abilities [25] as well as
Figure 1 BDNF protein levels distribution in 139 AFs (84
Val66Val individuals and 55 Met66 carriers). BDNF protein levels,
evaluated by ELISA method, are significantly reduced in Met carriers
versus non carriers The amount of BDNF expressed in pg/ml was
10.02 ± 9.62 for Met allele carriers and 15.88 ± 12.71 for non carriers
(Mann-Whithney test: p = 0.002). In the group of Met allele carriers,
the Met66Met are evidenced in black. Error Bars indicates the mean
of values ± standard deviation.
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altered hippocampal volume and gray matter density in
the frontal and prefrontal cortex [11,12]. Furthermore,
Stern and colleagues [26] have recently demonstrated a
brain deficiency in N-acetyl-aspartate levels, an indicator
of neuronal integrity, in subjects carrying the Met allele,
suggesting that this allele could play an important role
on hippocampal functionality and vitality and may have
putative implications for several psychiatric disorders.
To this support, a marked atrophy in several limbic
regions, was reported in patients with Major Depression,
Schizophrenia, Bipolar Disorder and other psychiatric
disorders [27], suggesting the presence of a deficiency in
neurogenesis and in synaptic plasticity, mechanisms
highly regulated by BDNF. Moreover, the Val66Met
polymorphism was also associated with alterations in
amygdala volume and in its activity in response to emo-
tional stimuli, suggesting an association between the
Met allele and an increased vulnerability for anxiety dis-
orders [28]. This polymorphism has been extensively
studied in relation to several psychiatric disorders
reporting often conflicting results. In particular, both
alleles have been associated with different mental disor-
ders and to date it is unknown how the two variants
may exert their influence on disease susceptibility. Prob-
ably, a mental disorders or a cognitive or brain imaging
endophenotype may be associated with the presence of
the Met allele, while a distinct condition may have been
associated with the Val variant. At this regard a recent
case-control study in psychiatric disorders [29] reported
that the Met allele significantly increases the risk for
schizophrenia and eating disorders whereas exerts a pro-
tective effect for substance-related disorders.
Furthermore, studies analyzing gene-environment
interactions [30,31] reported that BDNF Met carriers
exposed to early life stress events (ELS) have smaller
hippocampal and amygdala volumes, heart rate eleva-
tions, a decline in working memory and higher depres-
sion symptoms. In contrast, the combination of the
BDNF Val/Val genotype and ELS is associated with
increases in amygdala and prefrontal cortex grey matter
and with higher anxiety symptoms.
It is well known that human brain undergoes complex
morphological and functional changes during fetal
development. In particular, during the first and second
trimester of pregnancy, cortical subplate reaches its peak
of development, and cortical neurogenesis, characterized
by proliferation, migration and organization of neuronal
connections, is predominantly taking place [22,23].
Therefore, during this period the immature brain may
be particularly sensitive and vulnerable to a range of
intrauterine influences like stress exposure and inflam-
mation. During the first weeks of pregnancy Amniotic
Fluid derives principally from maternal plasma, getting
through to fetal membranes. Later, from tenth to
twentieth week, bidirectional diffusion between placenta,
umbilical cord and fetal skin occurs and in this period
the AF composition becomes very similar to fetal
plasma. Therefore, it may be assumed that the AF
BDNF content in this period reflects the total circulating
neurotrophin content of fetus [32].
In parallel, circulating BDNF levels in fetus could
reflect those in the brain since a correlation between
blood BDNF levels and the cortical protein expression
has been observed during neurodevelopment in rats
[33]. In this context, alterations of AF BDNF levels
induced by the presence of the BDNF polymorphism in
a critical period for brain development (15-17 weeks of
pregnancy), in concomitance with other susceptibility
genes or adverse intrauterine events, may represent a
vulnerability risk factor for brain development and
maturation. As previously reported, BDNF plays an
important role in neural proliferation, survival and dif-
ferentiation; therefore, reduced BDNF levels during CNS
development could influence the correct morphology of
specific cerebral regions as well as the cognitive and
memory abilities that are widely reported to be affected
in healthy subjects carrying Met allele. It is interesting
to notice that in the adulthood the Val66Met poly-
morphism does not affect the levels of the neurotrophin
in serum and plasma [34,35] and to date only Lang and
colleagues [36] reported a significant serum BDNF
increase in healthy subjects carrying Met allele. How-
ever, in this study the authors did not take in account
the influence of additional factors, such as drugs, life
style, environment and stress-life events, which interfere
with BDNF levels. Moreover, another possible explana-
tion for the discrepancy with our results could be the
specific impact of the Val66Met polymorphism on
BDNF levels during brain development and not in adult
life, where this effect could be hidden by confounding
factors putatively associated with the life style.
Some limitations of our study have to be mentioned.
The data about AF BDNF levels are from one point in
time, and the relationship between BDNF genotype and
AF BDNF levels may be different at other times during
gestation. Additionally, this study is correlational in nat-
ure and we cannot draw any definitive statements about
the consequences of BDNF Val66Met genotype on AF
protein levels. Larger studies in wider and better charac-
terized samples are needed to confirm these findings.
Conclusions
In conclusion, this study represents the first evidence of
the functionality of the BDNF Val66Met polymorphism
in the fetal environment showing a correlation between
the genotype and BDNF protein levels in AF during
neurodevelopment. Although these results are explora-
tive, they support a role of this polymorphism in the
Cattaneo et al. BMC Neuroscience 2010, 11:16
http://www.biomedcentral.com/1471-2202/11/16
Page 3 of 5
individual differences in brain morphology and function,
and in mental disorder susceptibility.
Methods
Sample collection
All the 139 amniotic fluid samples used in the study
were obtained by amniocentesis performed between the
15 and 17 weeks of pregnancy (mean of gestational
week: 16.1 ± 1.9) for fetal karyotype analysis requested
by mothers for their advanced age (mean of maternal
age = 35.7 ± 3.5). The inclusion/exclusion criteria were:
healthy women with Caucasoid origin, fetuses with 46
XX or 46 XY karyotypes, no infections or complications
during the previous gestational weeks and during the
amniocentesis. The fetus gender was so distributed: 73
males and 61 females.
After amniotic fluid collection, each sample was cen-
trifuged: the supernatant (AF) not necessary for alpha
fetoprotein dosage was taken anonymously and stored at
-80°C. Pellet fractions (AF cells, AFc) were cultured
firstly in Amniochrome medium, which was replaced
after 6-7 days with RPMI supplemented with 2 mM L-
glutamine and 20% of Fetal Bovine Serum (FBS) as for
routinely karyotype analysis. The leftover of AFc not
necessary for karyotype analysis was collected anon-
ymously without name or other detail, but with a num-
ber and bar-code. The study protocol has been
approved by the local ethic committee (CEIOC).
DNA purification and genotyping
DNA was isolated from AF cells using TRIZOL reagent,
according to the manufacturer’ protocol (Invitrogen)
and was quantified by Spectrophotometer (NanoDrop
Technologies, Delaware, USA). Primer pairs used to
amplify the sequences containing Val66Met were: BDNF
forward primer: AGGTGAGAAGAGTGATGACC and
BDNF reverse primer: CTGGACGTGTACAAGTCTGC.
The PCR reactions were performed in a final volume
of 25 μl with 2 μl of genomic DNA (100 ng/μl), 0.1 μl
of each primers pairs (100 μmol/ul), 0.7 mM of each
dNTPs (Eppendorf), 0.5 μl of MgCl2 2 mM, 1.25 units
of Taq Polymerase (Bioline) and buffer supplied by the
manufacturer (Bioline). The PCR products were then
sequenced using an ABI BigDye Terminator Cycle
Sequencing Kit and by 3130 XL DNA Sequencer Analy-
zer (Applied Biosystem).
BDNF determination in Amniotic Fluids
BDNF levels in AF samples (n = 139) were measured by
ELISA method using the human BDNF Quantikine kit
(R&D Systems, Minneapolis, USA). The BDNF content
was expressed as equivalent of human recombinant
BDNF protein (pg of BDNF protein/ml of AF). The
minimum detectable dose of the assay is typically less
than 20 pg/ml.
Statistical analysis
Analysis was performed using Statistical Product and
Service Solutions 13.0 Version (SPSS). Results are given
as mean value ± standard deviation. The Mann-Whith-
ney test was used to evaluate differences in quantitative
variables. The Pearson coefficient was used to evaluate
bivariate correlations.
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